A SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES REGARDING COVID-19

Year 2023, Volume: 26 Issue: 3, 853 - 870, 26.09.2023

Dolunay Özlem Zeybek , Dilara Arslan

Abstract

The pandemic brought many uncertainties about both the disease itself and the health system. Due to the high rate of transmission, the Covid-19 pandemic has caused individuals to experience problems in accessing health services not only for Covid-19 but also for other diseases wether chronic or acute. In the stages of struggling with the pandemic, conducting economic evaluation studies on Covid-19 was seen as important, taking into account the uncertainties and access issues encountered, in order to guide decision makers for rational decision-making and to use resources effectively and efficiently. This study aims systematically review the economic evaluation studies for the diagnosis, treatment, and control of Covid-19 disease. PubMed, Scopus, Web of Science and ULAKBİM databases were searched from December 2019 to July 2021 to identify the literature on economic evaluation studies related to Covid-19. As a result of the systematic search, 362 articles were identified as a result of the search made in the relevant databases. After the repetitive entries were removed, title and abstract scanning were performed, and 22 publications that met the inclusion criteria were examined within the scope of the study. It was observed that 68.18% of the studies were published in 2021 and 31.81% in 2020. 81.8% of the published studies have been conducted with cost-effectiveness, 9.09% with cost-benefit, and 4.54% with cost minimization and cost-utility analysis. The majority of the countries where the studies were conducted were in high-income countries, in 2021 and cost-effectiveness analysis. The subject of these studies is mostly related to screening and diagnostic tests for Covid-19 disease. There wasn't any study detected conducted in Turkey on the subject. More research on this particular subject is required in the future.

Keywords

Covid-19, Coronavirus, Systematic Screening, Economic Evaluation.

COVID-19 İLE İLGİLİ YAPILAN EKONOMİK DEĞERLENDİRME ÇALIŞMALARINA İLİŞKİN SİSTEMATİK İNCELEME

Abstract

Pandemi hem hastalığın kendisi hem de sağlık sistemi hakkında pek çok belirsizliği beraberinde getirmiştir. Covid-19 pandemisi, yüksek bulaşma hızı nedeniyle sadece Covid-19 için değil, kronik veya akut diğer hastalıklar için de bireylerin sağlık hizmetlerine erişimde sorun yaşamasına neden olmuştur. Pandemi ile mücadele aşamalarında, karar vericilerin akılcı karar almalarına rehberlik etmek ve kaynakları etkin ve verimli kullanmak amacıyla, yaşanan belirsizlikler ve erişim sorunları dikkate alınarak Covid-19 ile ilgili ekonomik değerlendirme çalışmalarının yapılması önemli görülmektedir. Bu çalışma, Covid-19 hastalığının tanı, tedavi ve kontrolüne yönelik ekonomik değerlendirme çalışmalarının sistematik olarak gözden geçirilmesini amaçlamaktadır. Covid-19 ile ilgili ekonomik değerlendirme çalışmalarına ilişkin literatürü belirlemek için 2019 Aralık ve 2021 Temmuz arasında PubMed, Scopus, Web of Science ve ULAKBİM veri tabanları taranmıştır. Yapılan sistematik tarama sonucunda İlgili veri tabanlarında yapılan tarama sonucunda 362 makale tespit edilmiştir. Tekrar eden kayıtlar kaldırıldıktan sonra başlık ve özet taraması yapılmış, dahil edilme kriterlerini karşılayan 22 yayın çalışma kapsamında incelenmiştir. Çalışmaların %68,18’inin 2021 yılında %31,81’inin 2020 yılında yayınlandığı görülmüştür. Yayınlanan çalışmaların %81,8’i maliyet etkililik, %9,09 maliyet fayda, %4,54’ü maliyet minimizasyon ve maliyet yararlanım analizidir. Çalışmaların yapıldığı ülkelerinin çoğunluğunun yüksek gelirli ülkelerde, 2021 yılında ve maliyet etkililik analizi olduğu görülmüştür. Bu çalışmaların konusunun çoğunlukla Covid-19 hastalığına yönelik tarama ve tanı testleri ile ilgilidir. Türkiye’den ise konuyla ilgili yapılmış herhangi bir çalışmaya rastlanmamıştır. Konuyla ilgili ilerleyen dönemlerde daha fazla araştırma yapılması gereklidir.

Keywords

Covid-19, Koronavirüs, Sistematik Tarama, Ekonomik Değerlendirme

References

• Aközlü, Z., & Öztürk Şahin, Ö. (2021). Covid-19 pandemisinde sağlık hizmetlerine erişim: Çocuk sağlığı nasıl etkilendi? Çocuk Dergisi, 21(2), 149–156.
• Bagepally, B. S., Haridoss, M., Natarajan, M., Jeyashree, K., & Ponnaiah, M. (2021). Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: Cost effectiveness analysis from Indian context. Clinical Epidemiology and Global Health, 10.
• Briggs, A., Sculpher, M., & Buxton, M. (1994). Uncertainty in the economic evaluation of health care technologies: The role of Sensitiviy Analysis. Health Economics, 3, 95-104.
• Broughel, J., & Kotrous, M. (2021). The benefits of coronavirus suppression: A cost-benefit analysis of the response to the first wave of COVID-19 in the United States. PLoS ONE, 16(6).
• Cleary, S. M., Wilkinson, T., Tamandjou Tchuem, C. R., Docrat, S., & Solanki, G. C. (2021). Cost‐effectiveness of intensive care for hospitalized COVID-19 patients: Experience from South Africa. BMC Health Services Research, 21(1), 1-10.
• Currie, J., Adamson, J., Bowden, B., Woolls, J., Jones, R., Healy, B., Heyburn, D., Shankar, A. G., & Howe, R. (2020). Impact of a novel community testing pathway for people with suspected COVID-19 in Wales: A cost-minimisation analysis. BMJ Open, 10(8), e038017.
• Doğan, İ., Ünal, A., & Çankaya, M. (2019). Sağlık hizmetlerinde ekonomik değerlendirme yöntemleri economic evaluation methods in health care. Fiscaoeconomia, 3(3), 152–168.
• Ebigbo, A., Römmele, C., Bartenschlager, C., Temizel, S., Kling, E., Brunner, J., & Messmann, H. (2021). Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment. Endoscopy, 53(2), 156-161.
• Ferguson, N. M., Laydon, D., Nedjati-Gilani, G., Imai, N., Ainslie, K., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z., Cuomo-Dannenburg, G., Dighe, A., Dorigatti, I., Fu, H., Gaythorpe, K., Green, W., Hamlet, A., Hinsley, W., Okell, L. C., van Elsland, S., … Ghani, A. C. (2020). Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College COVID-19 Response Team, London, March, 16.
• Gandjour, A. (2021). How many ıntensive care beds are justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Applied Health Economics and Health Policy, 19(2), 181–190.
• González López-Valcárcel, B., & Vallejo-Torres, L. (2020). The costs of COVID-19 and the cost-effectiveness of testing. Applied Economic Analysis, 29(85), 77–89.
• Hayran, O. E., & Sur, H. (2021). Covid-19 Epidemiyolojisi. In F. Budak (Ed.), Sağlık Yönetimi Bakış Açısıyla Covid-19 (2nd ed., pp. 7–26). Nobel Yayınevi.
• Jiang, Y., Cai, D., Chen, D., & Jiang, S. (2020). The cost-effectiveness of conducting three versus two reverse transcription-polymerase chain reaction tests for diagnosing and discharging people with COVID-19: Evidence from the epidemic in Wuhan, China. BMJ Global Health, 5(7), e002690.
• Jiang, Y., Cai, D., Chen, D., Jiang, S., Si, L., & Wu, J. (2021). Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. British Journal of Clinical Pharmacology, 87(11), 4386-4396.
• Kobelt, G. (2013). Health Economics: An Introduction to Economic Evaluation (Office of Health Economics, Ed.; 3rd ed.). Monographs.
• Kohli, M., Maschio, M., Becker, D., & Weinstein, M. C. (2021). The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine, 39(7), 1157-1164.
• López Seguí, F., Estrada Cuxart, O., Mitjà i Villar, O., Hernández Guillamet, G., Prat Gil, N., Maria Bonet, J., Isnard Blanchar, M., Moreno Millan, N., Blanco, I., Vilar Capella, M., Català Sabaté, M., Aran Solé, A., Argimon Pallàs, J. M., Clotet, B., & Ara del Rey, J. (2021). A cost-benefit analysis of the COVID-19 asymptomatic mass testing strategy in the North Metropolitan Area of Barcelona. International Journal of Environmental Research and Public Health, 18(13), 7028.
• Losina, E., Leifer, V., Millham, L., Panella, C., Hyle, E. P., Mohareb, A. M., Neilan, A. M., Ciaranello, A. L., Kazemian, P., & Freedberg, K. A. (2021). College campuses and COVID-19 mitigation: Clinical and economic value. Annals of Internal Medicine, 174(4), 472–483.
• Marco-Franco, J. E., Pita-Barros, P., González-De-julián, S., Sabat, I., & Vivas-Consuelo, D. (2021). Simplified mathematical modelling of uncertainty: Cost-effectiveness of Covid-19 vaccines in Spain. Mathematics, 9(5), 566.
• Ministry of Health. (2020). COVID-19 (SARS-CoV-2 ENFEKSİYONU) Genel Bilgiler, Epidemiyoloji ve Tanı. https://covid19.saglik.gov.tr/Eklenti/39551/0/covid-19rehberigenelbilgilerepidemiyolojivetanipdf.pdf Ministry of Health. (2022, March). Covid19. https://covid19.saglik.gov.tr/
• Podolsky, M. I., Present, I., Neumann, P. J., & Kim, D. D. (2022). A Systematic review of economic evaluations of COVID-19 interventions: Considerations of non-health Impacts and distributional issues. Value in Health, 25(8), 1298-1306.
• Reddy, K. P., Shebl, F. M., Foote, J. H. A., Harling, G., Scott, J. A., Panella, C., Fitzmaurice, K. P., Flanagan, C., Hyle, E. P., Neilan, A. M., Mohareb, A. M., Bekker, L. G., Lessells, R. J., Ciaranello, A. L., Wood, R., Losina, E., Freedberg, K. A., Kazemian, P., & Siedner, M. J. (2021). Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. The Lancet Global Health, 9(2), e120–e129.
• Ren, L. L., Wang, Y. M., Wu, Z. Q., Xiang, Z. C., Guo, L., Xu, T., Jiang, Y. Z., Xiong, Y., Li, Y. J., Li, X. W., Li, H., Fan, G. H., Gu, X. Y., Xiao, Y., Gao, H., Xu, J. Y., Yang, F., Wang, X. M., Wu, C., … Wang, J. W. (2020). Identification of a novel coronavirus causing severe pneumonia in human: A descriptive study. Chinese Medical Journal, 133(9), 1015–1024.
• Rezapour, A., Souresrafil, A., Peighambari, M. M., Heidarali, M., & Tashakori-Miyanroudi, M. (2021). Economic evaluation of programs against COVID-19: A systematic review. International Journal of Surgery, 85, 10–18. Risko, N., Werner, K., Offorjebe, O. A., Vecino-Ortiz, A. I., Wallis, L. A., & Razzak, J. (2020). Cost-effectiveness and return on investment of protecting health workers in low- And middle-income countries during the COVID-19 pandemic. PLoS ONE, 15(10), e0240503.
• Shaker, M., Abrams, E. M., & Greenhawt, M. (2021). A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. Journal of Allergy and Clinical Immunology: In Practice, 9(7), 2658-2668.
• Sheinson, D., Dang, J., Shah, A., Meng, Y., Elsea, D., & Kowal, S. (2021). A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Advances in Therapy, 38(4), 1811–1831.
• Shiell, A., Donaldson, C., Mitton, C., & Currie, G. (2002). Health economic evaluation. Journal of Epidemiology and Community Health, 56(2), 88.
• Shlomai, A., Leshno, A., Sklan, E. H., & Leshno, M. (2021). Modeling social distancing strategies to prevent SARS-CoV-2 spread in Israel: A cost-effectiveness analysis. Value in Health, 24(5), 607-614.
• Sookaromdee, P., & Wiwanitkit, V. (2021). New COVID-19 vaccines, its cost and shelf life: A cost effectiveness analysis. Archives of Medical Research, 52(4), 453.
• Stevenson, M., Metry, A., & Messenger, M. (2021). Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: Rapid cost-effectiveness analysis. Health Technology Assessment, 25(21), 1–68.
• Tawfik, G.M., Dila, K.A.S., Mohamed, M.Y.F., Tam, D.N.H., Kien, N.D., Ahmed, A.M., Huy, N.T. (2019). A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health, 47(1), 1-9.
• Temel, A., Ateş, A., & Eraç, B. (2021). COVID-19 pandemisinde mikrobiyolojik tanı yöntemleri. Türk Mikrobiyoloji Cemiyeti Dergisi, 51(2), 99–108.
• Turan, A., & Hamza Çelikyay, H. (2020). Türkiye’de KOVİD-19 ile mücadele: Politikalar ve aktörler. Uluslararası Yönetim Akademisi Dergisi, 3(1), 1–25.
• Wang, M., & Flessa, S. (2020). Modelling Covid-19 under uncertainty: what can we expect? European Journal of Health Economics, 21(5), 665–668.
• WHO. (2022a, April 14). WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https://covid19.who.int/
• WHO. (2022b). Therapeutics and COVID-19: living guideline. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2
• Yalçın Balçık, P., & Şahin, B. (2013). Sağlık hizmetlerinde maliyet etkililik analizi ve karar analizi. Hacettepe Sağlık İdaresi Dergisi, 16(2), 121–134.
• Yavuz, E. (2020). COVID-19 aşıları. Türk Aile Hekimliği Dergisi, 24(4), 227–234.
• Yıldız, A., & Bulut, S. (2021). COVID-19 pandemi döneminde sağlık hizmetleri kullanımının değerlendirilmesi. Türkiye Klinikleri Sağlık Bilimleri Dergisi, 6(4), 928–938.
• Zala, D., Mosweu, I., Critchlow, S., Romeo, R., & McCrone, P. (2020). Costing the COVID-19 pandemic: An exploratory economic evaluation of hypothetical suppression policy in the United Kingdom. Value in Health, 23(11), 1432–1437.
• Zhao, H., & Feng, Z. (2020). Staggered release policies for COVID-19 control: Costs and benefits of relaxing restrictions by age and risk. Mathematical Biosciences, 326.